Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (DE:LX31)
BERLIN:LX31
RESEARCH TOOLSreports
Lexicon Pharmaceuticals (LX31) Stock Price & Analysis
0 Followers
LX31 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.88 - €4.14
Previous Close€1.58
Volume0.00
Average Volume (3M)2.30K
Market Cap
€389.86M
Enterprise Value€242.44M
Total Cash (Recent Filing)$256.74M
Total Debt (Recent Filing)$98.77M
Price to Earnings (P/E)N/A
Beta1.68
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding246,236,753
10 Day Avg. Volume0
30 Day Avg. Volume2,303
Standard Deviation0.18
R-Squared0.00342
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.86
Price to Sales (P/S)22356.17
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue681.01
Enterprise Value/Gross Profit1.74K
Enterprise Value/Ebitda-20.52
Forecast
1Y Price Target
€5.90Price Target Upside259.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Lexicon Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial StabilityLexicon's strong cash position, bolstered by a recent $250M fundraising, underscores the company's financial stability and ability to invest in future growth.
Market OpportunityThe potential market growth for Inpefa is bolstered by its anticipated adoption, supported by differentiated data in hospitalized heart failure and its inclusion in key consensus guidelines.
Product PipelineLexicon's diversified late-stage pipeline, including plans for resubmitting the NDA for T1D with CKD, highlights ongoing development efforts and commitment to addressing unmet medical needs.
Bears Say
Earnings1Q24 Inpefa sales were $1.1M, below analyst's expectations of $2.0M.
Product DifferentiationNeed for more visibility on the differentiation of the Pain program.
Sales ForecastAnalyst has lowered the future sales estimates for Inpefa, indicating a cautious stance on its market performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.82% Other Institutional Investors
99.18% Public Companies and
Individual Investors
LX31 FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was €0.88 and its highest was €4.14 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Currently, no data Available
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 89 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on May 02, 2024. The company reported -€0.187 earnings per share for the quarter, missing the consensus estimate of -€0.168 by -€0.019.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexicon Pharmaceuticals have?
Currently, no data Available
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -€0.187 in its last earnings report, missing expectations of -€0.168. Following the earnings report the stock price went up 3.605%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is EntryPoint Capital, LLC. It holds Lexicon Pharmaceuticals’s shares valued at 496K.
---
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.90 (259.92% Upside)
€5.90 (259.92% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.57%
12-Months-Change
Fundamentals
Return on Equity
-167.06%
Trailing 12-Months
Asset Growth
18.08%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
LX31 Earnings Call
Q1 2024
0:00 / 0:00
---
LX31 Stock 12 Months Forecast
Average Price Target
€5.90
▲(259.92% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Ionis Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Sarepta Therapeutics
―
Xencor
―
Best Analysts Covering LX31
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-7.58%
reiterated a buy rating 2 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -7.58% per trade.
---